The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.
“There were lower rates of CRS and ICANS than in ZUMA-2 and most side effects were grade 1. These real-world experiences are very helpful, because clinical trials use a selected population of patients. We're seeing similar responses and toxicities in the real-world setting as the clinical trials. I think it’s very encouraging data.”
Currently approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies include lisocabtagene maraleucel (Breyanzi), axicabtagene cliolecleucel (Yescarta), brexucabtagene autoleucel (Tecartus)and ciltacabtagene autoleucel (Carvykti). As more CAR T therapies come to market, clinicians are beginning to see the long-term impact of these treatments in the clinic.
Among these clinicians is Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute. Ghosh has first-hand experience with these CAR T therapies on the clinic side and has seen their impact in patients with hematologic malignancies such as lymphomas.
CGTLive spoke to Ghosh to learn more about the future trajectory of CAR T-cell therapies in lymphomas. He discussed recent data seen in real-world experience studies of CAR T-cell therapies.